TNFSF13B and systemic lupus erythematosus: In addition, the observation that IRF5 and BLyS contribute to disease pathogenesis through different mechanisms suggests the possibility that combined BLyS and IRF5 inhibition might be a more effective therapy for lupus than inhibition of either pathway alone.